Abatacept in the treatment of rheumatoid arthritis

Mostrar otras versiones (1)

Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA). Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA who have failed to respond to disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Vital, Edward M, Emery, Paul
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2006
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936358/
https://www.ncbi.nlm.nih.gov/pubmed/18360649
Descripción
Sumario:Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA). Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA who have failed to respond to disease-modifying antirheumatic drugs (DMARDs) and antitumor necrosis factor-alpha (TNF-α) biologic agents. Safety profile is favorable in combination with DMARDs. The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

Ejemplares similares